Meeting NewsVideo

VIDEO: No increased safety risk associated with increasing tocilizumab exposure

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Shalini Mohan, MD, discussed a study that provided an update of the safety of tocilizumab treatment in patients with rheumatoid arthritis, using data from multiple clinical trials and the global tocilizumab post-marketing safety database. According to Mohan, the results were consistent with previous safety reports, and indicate there is no evidence of increased safety risk with increasing exposure to tocilizumab.

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Shalini Mohan, MD, discussed a study that provided an update of the safety of tocilizumab treatment in patients with rheumatoid arthritis, using data from multiple clinical trials and the global tocilizumab post-marketing safety database. According to Mohan, the results were consistent with previous safety reports, and indicate there is no evidence of increased safety risk with increasing exposure to tocilizumab.

    See more from American College of Rheumatology Annual Meeting